Please login to the form below

Endocyte

This page shows the latest Endocyte news and features for those working in and with pharma, biotech and healthcare.

The year saw it spend $8.7bn on acquiring gene therapy company AveXis and radiotherapy specialists Endocyte for $2.8bn.

Novartis: pipeline will generate 60 filings in three years

Endocyte adding .
Novartis culls pipeline to focus on most transformative science

$8.7bn, and cancer specialist Endocyte for $2.1bn.
Novartis buys cancer specialist Endocyte for $2.1bn

Heading up Endocyte’s pipeline is. 177. Lu-PSMA-617, a potential first-in-class drug for the treatment of metastatic castration-resistant prostate cancer (CRPC). ... Novartis said radiopharma is a “key growth driver” for its business and that
Merck's vintafolide fails ovarian cancer trial

If vintafolide is dropped, Endocyte will have to refocus its efforts on EC1456, a cancer drug for folate receptor-positive cancers in phase I testing. ... Shares in Endocyte are currently hovering above $6.50, having traded as high as $33.70 in the last
EMA backs Janssen rare disease drug for approval

it. Staying in the orphan disease area the CHMP also gave the nod to Endocyte's Vynfinit (vintafolide), a treatment for platinum-resistant ovarian cancer, along with two companion diagnostic drugs

More from news
Approximately 3 fully matching, plus 8 partially matching documents found.

Deal Watch October 2018

Novartis. Deal Type. Deal with. Details. Value. Acquisition. Endocyte. Portfolio of products and technology for. ... Endocyte’s adaptor controlled CAR‐T technology delivers the molecule FITC to the tumour through a tumour‐targeted ligand.
Charting a course for expansion

and eastern Europe - and US biotech Endocyte.

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Endocyte appoints Parexel's Scot Harper to oversee clinical trials

He also previously served at Novartis and Lilly. Endocyte has appointed Dr Scot Harper as VP, clinical operations, where he will be responsible for clinical trial operations at the US biopharma ... In addition, Endocyte says it has three new drug
Endocyte brings in senior figures from BMS and Amgen

The appointments come at a crucial time for Endocyte as it prepares for the approval and launch of cancer drugs vintafolide (in partnership with Merck &Co) and etarfolatide. ... The two additions follow the hire in July 2012 of Endocyte's first chief

More from appointments
Approximately 2 fully matching, plus 0 partially matching documents found.

Account Manager / Senior Account Manager - Creative MedComms - C...: Excellent Remuneration

Account Manager, Medical Communications and Marketing: £30, 000 – £40, 000 benefits and bonus

Programme Manager / Programme Director – Medical Education - Buc...: Salary TBC

Add my company

Welcome to Frontera Group where our agencies immerse you into the world of the patient....

The Exhibition Hall: Past, Present and Future: As I sit here at another pharma conference, I start to reflect on how they have changed over the years....
Success breeds success: This week we received the exciting news that we have been shortlisted for the Times Business Awards 2019, Tunbridge Wells in the 'Best Business 1-25 Employees' category....
Turning learning into action: The challenge of behaviour change: ...